Table 3.
Variable | Yes, No. (%) |
No, No. (%) |
P-value |
---|---|---|---|
No. of patients | 38 (11.2) | 301 (88.8) | |
Age in years, median (range) | 68 (38–90) | 64 (23–88) | 0.54 |
Gender, male | 24 (63.2) | 190 (63.1) | 1.00 |
Underlying disease/condition | |||
Cardiovascular disease | 7 (18.4) | 42 (13.9) | 0.46 |
Diabetes mellitus | 20 (52.6) | 117 (38.9) | 0.12 |
Uremia requiring dialysis | 7 (18.4) | 59 (19.6) | 1.00 |
Decompensated liver cirrhosis | 6 (15.8) | 41 (14.6) | 0.80 |
Malignancies | 7 (18.4) | 57 (18.9) | 1.00 |
Prosthetic device implantation | 5 (13.2) | 36 (11.9) | 0.79 |
Severity-of-illness markera | |||
Nosocomial acquisition | 31 (81.6) | 214 (71.1) | 0.25 |
Intensive care unit admission | 12 (31.6) | 63 (20.9) | 0.15 |
APACHE II score, median (range) | 15 (1–38) | 11 (2–29) | 0.15 |
APACHE II score >15 | 10 (26.3) | 34 (11.3) | 0.02 |
Source of infectionb | |||
Catheter-related infection | 1 (2.6) | 39 (12.9) | 0.07 |
Endovascular infection | 0 | 9 (2.9) | 0.61 |
Soft-tissue infection | 13 (34.2) | 85 (28.2) | 0.45 |
Osteomyelitis | 8 (21.1) | 59 (19.6) | 0.83 |
Urinary tract infection | 0 | 4 (1.3) | 1.00 |
Pneumonia | 15 (39.5) | 36 (11.9) | <0.01 |
Primary bacteremia | 6 (15.8) | 68 (22.6) | 0.41 |
Timing of initiating glycopeptide therapy | |||
Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO growth | 23 (60.5) | 168 (55.8) | 0.61 |
BC: blood culture; MRSA: methicillin-resistant S. aureus; No.: number; SLO: Staphylococcus-like organism.
aAt time of blood culture sampling.
bSome patients had more than one infected site.